SV Life Sciences and Health Enterprise Partners Announce Formation of Jet Health
Accomplished healthcare executive Jim Glynn to lead home healthcare platform For Immediate Release Irvine, CA, April 15, 2016 – SV Life Sciences Advisers (“SVLS”) and Health Enterprise Partners (“HEP”) announced today that they have partnered with experienced healthcare services executive Jim Glynn to form Jet Health, Inc. (“Jet Health”).
SV Life Sciences Fund IV invested in Kalvista as part of a $5.2m Series A2 extension financing round. Kalvista is a Pharmaceutical and Ophthalmology company developing Plasma Kallikrein inhibitors. ...
SV Life Sciences Fund IV notes that Icon acquired Aptiv from its owners, SV Life Sciences and others for $143.5m. Aptiv is a global development services company focused on enhancing clinical trial decision making and drug and device development through the design, simulation and execution of adaptive clinical trials and a novel statistical sampling approach to risk based monitoring.
SV Life Sciences Advisers notes that Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing. Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All existing venture investors, HBM Ventures, Novo A/s, SV Life Sciences, BioMedinvest and Venture Incubator participated in the round.
SV Life Sciences Advisers notes that Ophthotech successfully listed on NASDAQ on 25 September 2013 NEW YORK, Sep 24, 2013 (BUSINESS WIRE) -- Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Ophthotech.
Transenterix merger with SafeStitch Medical (OTCBB: SFES)
SV Life Sciences Advisers notes that TransEnterix successfully merged with SafeStitch Medical on 4 September 2013. $30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders Combined Company to be Renamed TransEnterix MIAMI & RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--September 04, 2013 SafeStitch Medical, Inc. (OTCBB: SFES) and TransEnterix, Inc.
Second tranche of Series B to accelerate development and commercialization of new flexible surgical tools SV Life Sciences notes that SV Life Sciences Fund IV invested in TransEnterix, maker of flexible medical devices that are changing how minimally invasive surgeries are performed today as part of a $15m Series B financing round. RESEARCH TRIANGLE PARK, N.C. – TransEnterix Inc. has closed $15 million in venture capital financing.
SV Life Sciences notes that SV Life Sciences Fund IV invested in Vantia Therapeutics, an emergine pharmaceutifcal company developing novel, small molecule drugs as part of a £4m Series B financing round. ...
SV Life Sciences notes that SV Life Sciences Fund IV invested in Halscion, developing a device for the reduction in the appearance of scars resulting from acute surgical wounds as part of a $3.5m Series A financing round. A Suwanee based biotech has raised $3.5 million, according to a Securities & Exchange Commission filing. Halscion Inc. is developing a device for the reduction in the appearance of scars resulting from acute surgical wounds. The company has raised $4.
In the UK, SV Life Sciences Advisers LLP (registered in England OC 308830, VAT 852 5150 39) is authorised and regulated by the Financial Conduct Authority ('FCA'). It is entered into the FCA's register and with registration number 409123. The registered office is 71 Kingsway, London, WC2B 6ST.